ALK B ALK-ABELLO A/S

Invitation til præsentation af ALK’s årsrapport for 2024 onsdag den 19. februar 2025

Invitation til præsentation af ALK’s årsrapport for 2024 onsdag den 19. februar 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør sin årsrapport for 2024 om morgenen onsdag den 19. februar 2025.

ALK afholder senere samme dag kl. 13.30 (CET) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål.

ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef. 

Live audio-webcast

Mødet audiocastes live på , hvor genafspilning af præsentationen også vil være tilgængelig.

Telefonkonference

Hvis du ønsker at deltage via telefon, bedes du tilmelde dig via dette link:

. Følg instruktionerne på siden. Efter tilmeldingen vil du modtage en e-mail fra  med opkaldsdetaljer, inklusive et password og en pinkode. Husk at tjekke dit spamfilter. Vi anbefaler tilmelding senest dagen før.

Præsentation

Præsentationen vil være tilgængelig kort før start på .

ALK-Abelló A/S

For yderligere oplysninger kontakt venligst:

Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525

Presse: Maiken Riise Andersen, tlf. 5054 1434

Om ALK

ALK er en global, specialiseret medicinalvirksomhed med fokus på allergi og allergisk astma. Virksomheden markedsfører allergi-immunterapi og andre produkter og serviceydelser til mennesker med allergi og allergilæger. Virksomheden har hovedkvarter i Hørsholm, beskæftiger omkring 2.800 mennesker over hele verden og er noteret på Nasdaq Copenhagen. Find mere information på .

Vedhæftet fil



EN
12/02/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ITULATEK® approved for treatment of children and adolescents in Canada

ITULATEK® approved for treatment of children and adolescents in Canada ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, hazel, and/or oak, in children, adolescents, and adults five to 65 years of age in Canada. Outside Europe, Can...

May 8, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
05/08/25 May 8, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
05/06/25 May 6, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Three-month interim report (Q1) 2025 (unaudited) - English version onl...

Three-month interim report (Q1) 2025 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på  engelsk. ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free cash flow almost tripled. Outlook remains unchanged. Performance highlights Comparative figures for Q1 2024 are shown in brackets. Growth rates are ...

May 6, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Three-month interim report (Q1) 2025 (unaudited)

Three-month interim report (Q1) 2025 (unaudited) ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free cash flow almost tripled. Outlook remains unchanged. Performance highlights Comparative figures for Q1 2024 are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated. Total revenue increased by 12% to ...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch